{"transactions":[{"id":4633017,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":false,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":60000,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633016,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":262,"price":116.12,"value":30423.44,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $116.16 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":666568,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633015,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":8230,"price":115.4,"value":949742.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.94 to $115.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":666830,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633014,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":7601,"price":114.43,"value":869782.43,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.94 to $114.91 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":675060,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633013,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":4876,"price":113.24,"value":552158.24,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.95 to $113.88 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":682661,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633012,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":5506,"price":112.42,"value":618984.52,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.97 to $112.92 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":687537,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633011,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"sale","planned":true,"acquired":false,"shares":3525,"price":111.44,"value":392826.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.93 to $111.90, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":693043,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4633010,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-10-02T01:20:12.000Z","date":"2026-10-01","kind":"exercise","planned":true,"acquired":true,"shares":30000,"price":2.08,"value":62400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."}],"balance_after":696568,"source":{"system":"sec-edgar","filing":"0001193125-26-410839","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526410839/ownership.xml","form_type":"4"}},{"id":4862,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":10235,"kind":"person","name":"Adams Brian","position":1,"cik":"0001636994","reported_name":"Adams Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-04T22:00:03.000Z","date":"2026-09-04","kind":"sale","planned":false,"acquired":false,"shares":2137,"price":117.57,"value":251247.09,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.38 to $117.85, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":50254,"source":{"system":"sec-edgar","filing":"0001193125-26-383874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526383874/ownership.xml","form_type":"4"}},{"id":4861,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":10235,"kind":"person","name":"Adams Brian","position":1,"cik":"0001636994","reported_name":"Adams Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-04T22:00:03.000Z","date":"2026-09-04","kind":"sale","planned":false,"acquired":false,"shares":3025,"price":116.81,"value":353350.25,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.09 to $117.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":52391,"source":{"system":"sec-edgar","filing":"0001193125-26-383874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526383874/ownership.xml","form_type":"4"}},{"id":4860,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":10235,"kind":"person","name":"Adams Brian","position":1,"cik":"0001636994","reported_name":"Adams Brian","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-04T22:00:03.000Z","date":"2026-09-04","kind":"sale","planned":false,"acquired":false,"shares":1209,"price":115.55,"value":139699.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. Such sales were automatic and not in the discretion of the Reporting Person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.09 to $116.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":55416,"source":{"system":"sec-edgar","filing":"0001193125-26-383874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526383874/ownership.xml","form_type":"4"}},{"id":702997,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":28555,"kind":"person","name":"Rooney Terence","position":1,"cik":"0002146464","reported_name":"Rooney Terence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-27T22:34:16.000Z","date":"2026-07-27","kind":"grant","planned":false,"acquired":true,"shares":76000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares underlying this stock option shall vest on July 27, 2027, with the remainder vesting in thirty-six (36) equal monthly installments thereafter, subject to the reporting person's continued employment through each vesting date."}],"balance_after":76000,"derivative":{"exercise_price":110.05,"expiration_date":"2036-07-26","underlying":"Common Stock","underlying_shares":76000},"source":{"system":"sec-edgar","filing":"0001193125-26-318408","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526318408/ownership.xml","form_type":"4"}},{"id":702996,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":28555,"kind":"person","name":"Rooney Terence","position":1,"cik":"0002146464","reported_name":"Rooney Terence","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2026-07-27T22:34:16.000Z","date":"2026-07-27","kind":"grant","planned":false,"acquired":true,"shares":38000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Represents restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of the Issuer's common stock upon vesting and settlement. The RSUs shall vest in four equal annualinstallments following July 27, 2026, subject to the reporting person's continued employment through each vesting date."}],"balance_after":38000,"source":{"system":"sec-edgar","filing":"0001193125-26-318408","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526318408/ownership.xml","form_type":"4"}},{"id":713982,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-08T00:00:03.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":false,"shares":4441,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":14284,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":4441},"source":{"system":"sec-edgar","filing":"0001193125-26-297817","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526297817/ownership.xml","form_type":"4"}},{"id":713981,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-08T00:00:03.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":false,"shares":45559,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":90000,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":45559},"source":{"system":"sec-edgar","filing":"0001193125-26-297817","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526297817/ownership.xml","form_type":"4"}},{"id":713980,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-08T00:00:03.000Z","date":"2026-07-07","kind":"sale","planned":true,"acquired":false,"shares":50000,"price":119,"value":5950000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."}],"balance_after":666568,"source":{"system":"sec-edgar","filing":"0001193125-26-297817","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526297817/ownership.xml","form_type":"4"}},{"id":713979,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-08T00:00:03.000Z","date":"2026-07-07","kind":"exercise","planned":true,"acquired":true,"shares":50000,"price":2.08,"value":104000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."}],"balance_after":716568,"source":{"system":"sec-edgar","filing":"0001193125-26-297817","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526297817/ownership.xml","form_type":"4"}},{"id":718201,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":61378,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.33,"expiration_date":"2030-05-13","underlying":"Common Stock","underlying_shares":61378},"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718200,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":3200,"price":117.7029,"value":376649.28,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.55 to $118.09, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":244883,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718199,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":6153,"price":116.9937,"value":719862.2361,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.49 to $117.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":248083,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718198,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":7971,"price":115.8171,"value":923178.1041,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.49 to $116.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":254236,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718197,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":51375,"price":114.7696,"value":5896288.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.49 to $115.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":262207,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718196,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":4110,"price":114.1875,"value":469310.625,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.49 to $114.48, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":313582,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718195,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":1100,"price":112.7881,"value":124066.91,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.49 to $113.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":317692,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718194,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":1700,"price":111.5671,"value":189664.07,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.41 to $112.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":318792,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718193,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":1500,"price":110.5397,"value":165809.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.37 to $110.96, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":320492,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718192,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32922,"kind":"person","name":"Jacobs Bruce N.","position":1,"cik":"0001821074","reported_name":"Jacobs Bruce N.","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:07.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":61378,"price":5.33,"value":327144.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 23, 2026 adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 373 shares acquired under the Registrant's employee stock purchase plan."}],"balance_after":321992,"source":{"system":"sec-edgar","filing":"0001193125-26-295090","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295090/ownership.xml","form_type":"4"}},{"id":718191,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32921,"kind":"person","name":"Goodman Noah","position":1,"cik":"0002060075","reported_name":"Goodman Noah","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:04.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":3389,"price":114.29,"value":387328.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated December 10, 2025 adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 373 shares acquired under the Registrant's employee stock purchase plan."}],"balance_after":47179.438,"source":{"system":"sec-edgar","filing":"0001193125-26-295089","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000119312526295089/ownership.xml","form_type":"4"}},{"id":719532,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":false,"shares":80000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"The shares underlying this stock option are fully vested and exercisable."}],"balance_after":135559,"derivative":{"exercise_price":2.08,"expiration_date":"2029-11-13","underlying":"Common Stock","underlying_shares":80000},"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719531,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":3336,"price":116.559,"value":388840.824,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.29 to $116.63, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":666568,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719530,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":44050,"price":115.6883,"value":5096069.615,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.31 to $116.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":669904,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719529,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":24105,"price":114.9555,"value":2771002.3275,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.29 to $115.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":713954,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719528,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":6626,"price":113.9758,"value":755203.6508,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.36 to $114.23, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":738059,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719527,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"sale","planned":true,"acquired":false,"shares":1883,"price":112.8046,"value":212411.0618,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.28 to $113.27, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."}],"balance_after":744685,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":719526,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":31822,"kind":"person","name":"Mainolfi Nello","position":1,"cik":"0001821189","reported_name":"Mainolfi Nello","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2026-07-02T22:30:03.000Z","date":"2026-07-01","kind":"exercise","planned":true,"acquired":true,"shares":80000,"price":2.08,"value":166400.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"These transactions were effected pursuant to a Rule 10b5-1 trading plan dated March 24, 2026 adopted by the reporting person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"This number includes 373 shares acquired under the Registrant's employee stock purchase plan."}],"balance_after":746568,"source":{"system":"sec-edgar","filing":"0001193125-26-295088","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1821189/000119312526295088/ownership.xml","form_type":"4"}},{"id":718190,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":130,"price":111.2,"value":14456.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":462856,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718189,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":1078,"price":110.67,"value":119302.26,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":462986,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718188,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":1104,"price":109.75,"value":121164.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":464064,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718187,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":1498,"price":108.28,"value":162203.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":465168,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718186,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":2698,"price":107.76,"value":290736.48,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":466666,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718185,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":2133,"price":106.63,"value":227441.79,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":469364,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718184,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":770,"price":105.78,"value":81450.6,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F11","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":471497,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718183,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":934,"price":111.2,"value":103860.8,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2384685,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718182,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":7723,"price":110.67,"value":854704.41,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2385619,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718181,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":7968,"price":109.75,"value":874488.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2393342,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718180,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":10848,"price":108.28,"value":1174621.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2401310,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718179,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":19419,"price":107.76,"value":2092591.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2412158,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718178,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":14798,"price":106.63,"value":1577910.74,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2431577,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":718177,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-07-02T21:39:08.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":5549,"price":105.78,"value":586973.22,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"shares","element":"transactionShares","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (3) and (5) through (10)."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"The number of shares disposed and the number of shares owned following reported transaction were inadvertently misreported on the original Form 4. This represents to correct number."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F4","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2446375,"source":{"system":"sec-edgar","filing":"0001451612-26-000022","document":"form4a-07022026_090703.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000022/form4a-07022026_090703.xml","form_type":"4/A","original_submission_date":"2026-06-30"}},{"id":722878,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:32:18.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":157,"price":111.2,"value":17458.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":461794,"source":{"system":"sec-edgar","filing":"0001451612-26-000020","document":"form4-06302026_090614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000020/form4-06302026_090614.xml","form_type":"4"}},{"id":722877,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:32:18.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":1199,"price":110.67,"value":132693.33,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":461951,"source":{"system":"sec-edgar","filing":"0001451612-26-000020","document":"form4-06302026_090614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000020/form4-06302026_090614.xml","form_type":"4"}},{"id":722876,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:32:18.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":1239,"price":109.75,"value":135980.25,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":463150,"source":{"system":"sec-edgar","filing":"0001451612-26-000020","document":"form4-06302026_090614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000020/form4-06302026_090614.xml","form_type":"4"}},{"id":722875,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:32:18.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":1688,"price":108.28,"value":182776.64,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4) through (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F7","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":464389,"source":{"system":"sec-edgar","filing":"0001451612-26-000020","document":"form4-06302026_090614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000020/form4-06302026_090614.xml","form_type":"4"}},{"id":722874,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:32:18.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":907,"price":111.2,"value":100858.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.09 to $111.63 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2385747,"source":{"system":"sec-edgar","filing":"0001451612-26-000020","document":"form4-06302026_090614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000020/form4-06302026_090614.xml","form_type":"4"}},{"id":722873,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:32:18.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":7602,"price":110.67,"value":841313.34,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.09 to $111.08 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2386654,"source":{"system":"sec-edgar","filing":"0001451612-26-000020","document":"form4-06302026_090614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000020/form4-06302026_090614.xml","form_type":"4"}},{"id":722872,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:32:18.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":7833,"price":109.75,"value":859671.75,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.034 to $109.96 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2394256,"source":{"system":"sec-edgar","filing":"0001451612-26-000020","document":"form4-06302026_090614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000020/form4-06302026_090614.xml","form_type":"4"}},{"id":722871,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:32:18.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":10658,"price":108.28,"value":1154048.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.0326 to $109.019 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2) and (4) through (6)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2402089,"source":{"system":"sec-edgar","filing":"0001451612-26-000020","document":"form4-06302026_090614.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000020/form4-06302026_090614.xml","form_type":"4"}},{"id":722870,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":3024,"price":107.76,"value":325866.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":466077,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":30,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722869,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":2318,"price":106.63,"value":247168.34,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":469101,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":29,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722868,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":848,"price":105.78,"value":89701.44,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":471419,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":28,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722867,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":19093,"price":107.76,"value":2057461.68,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F18","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.03 to $108.0293 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2412747,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":27,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722866,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":14613,"price":106.63,"value":1558184.19,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F17","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.0271 to $106.96 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2431840,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":26,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722865,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-29","kind":"sale","planned":true,"acquired":false,"shares":5471,"price":105.78,"value":578722.38,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $105.015 to $106.0145 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2446453,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":25,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722864,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":1729,"price":118.66,"value":205163.14,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.2717 to $119.035 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":472267,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":24,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722863,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":3069,"price":117.85,"value":361681.65,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.2728 to $118.2599 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":473996,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":23,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722862,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":1701,"price":117.09,"value":199170.09,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.2731 to $117.2668 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":477065,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722861,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":952,"price":115.69,"value":110136.88,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.27 to $116.2626 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":478766,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722860,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":3896,"price":114.94,"value":447806.24,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.2766 to $115.2672 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":479718,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722859,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":2083,"price":113.97,"value":237399.51,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.2614 to $114.246 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":483614,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722858,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":78,"price":112.49,"value":8774.22,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.1843 to $113.0139 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":485697,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722857,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":1442,"price":111.51,"value":160797.42,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.1057 to $111.9188 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":485775,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722856,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":1579,"price":110.49,"value":174463.71,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.02 to $111.0075 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":487217,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722855,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":4562,"price":109.79,"value":500861.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.02 to $110.0166 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":488796,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722854,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":32402,"price":108.14,"value":3503952.28,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to 108.9725 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":493358,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722853,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":3958,"price":107.57,"value":425762.06,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.995 to $107.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) through (14), and (16) through (18)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F15","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":525760,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722852,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":12390,"price":118.66,"value":1470197.4,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F14","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $118.2717 to $119.035 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2451924,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722851,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":22046,"price":117.85,"value":2598121.1,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $117.2728 to $118.2599 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2464314,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722850,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":12181,"price":117.09,"value":1426273.29,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $116.2731 to $117.2668 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2486360,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722849,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":6821,"price":115.69,"value":789121.49,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $115.27 to $116.2626 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2498541,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722848,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":27951,"price":114.94,"value":3212687.94,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $114.2766 to $115.2672 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2505362,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722847,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":14913,"price":113.97,"value":1699634.61,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $113.2614 to $114.246 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2533313,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722846,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":555,"price":112.49,"value":62431.95,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $112.1843 to $113.0139 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2548226,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722845,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":10366,"price":111.51,"value":1155912.66,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $111.1057 to $111.9188 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2548781,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722844,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":11277,"price":110.49,"value":1245995.73,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $110.02 to $111.0075 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2559147,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722843,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":32624,"price":109.79,"value":3581788.96,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $109.02 to $110.0166 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2570424,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722842,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":231007,"price":108.14,"value":24981096.98,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.00 to 108.9725 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2603048,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":722841,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-30T21:30:20.000Z","date":"2026-06-26","kind":"sale","planned":true,"acquired":false,"shares":28296,"price":107.57,"value":3043800.72,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.995 to $107.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold each separate price within the ranges set forth in footnotes (2), (4) through (14), and (16) through (18)."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"These shares are held directly by Atlas Venture Fund X, L.P. (\"Atlas Venture Fund X\"). The general partner of Atlas Venture Fund X is Atlas Venture Associates X, L.P. (\"AVA X LP\"). Atlas Venture Associates X, LLC (\"AVA X LLC\") is the general partner of AVA X LP. The Reporting Person is a member of AVA X LLC and disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund X, except to the extent of his pecuniary interest therein, if any."}],"balance_after":2834055,"source":{"system":"sec-edgar","filing":"0001451612-26-000018","document":"form4-06302026_090613.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000018/form4-06302026_090613.xml","form_type":"4"}},{"id":725874,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2026-06-26T22:48:12.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":51858,"price":106.5,"value":5522877.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F5","text":"Securities held in a certain Partners managed account (the \"Partners Managed Account\"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F5","text":"Securities held in a certain Partners managed account (the \"Partners Managed Account\"). Partners may be deemed to have indirect beneficial ownership of the securities of the Issuer held by the Partners Managed Account for purposes of Rule 16a-1(a)(2) because the securities account for more than 10% of the market value of the portfolio of the Partners Managed Account as of the reporting date. Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account."}],"balance_after":78787,"source":{"system":"sec-edgar","filing":"0000921895-26-001688","document":"form407422010_06262026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001688/form407422010_06262026.xml","form_type":"4"}},{"id":725873,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2026-06-26T22:48:12.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":113289,"price":106.5,"value":12065278.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS."}],"balance_after":240123,"source":{"system":"sec-edgar","filing":"0000921895-26-001688","document":"form407422010_06262026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001688/form407422010_06262026.xml","form_type":"4"}},{"id":725872,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2026-06-26T22:48:12.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":627597,"price":106.5,"value":66839080.5,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2."}],"balance_after":1592261,"source":{"system":"sec-edgar","filing":"0000921895-26-001688","document":"form407422010_06262026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001688/form407422010_06262026.xml","form_type":"4"}},{"id":725871,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":30208,"kind":"organization","name":"BVF PARTNERS L P/IL","position":1,"cik":"0001055947","reported_name":"BVF PARTNERS L P/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30209,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND L P","position":2,"cik":"0000918923","reported_name":"BIOTECHNOLOGY VALUE FUND L P","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30210,"kind":"organization","name":"BVF I GP LLC","position":3,"cik":"0001803805","reported_name":"BVF I GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30211,"kind":"organization","name":"BIOTECHNOLOGY VALUE FUND II LP","position":4,"cik":"0001102444","reported_name":"BIOTECHNOLOGY VALUE FUND II LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30212,"kind":"organization","name":"BVF II GP LLC","position":5,"cik":"0001803806","reported_name":"BVF II GP LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30213,"kind":"organization","name":"Biotechnology Value Trading Fund OS LP","position":6,"cik":"0001660683","reported_name":"Biotechnology Value Trading Fund OS LP","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30214,"kind":"organization","name":"BVF Partners OS Ltd.","position":7,"cik":"0001660684","reported_name":"BVF Partners OS Ltd.","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30215,"kind":"organization","name":"BVF GP HOLDINGS LLC","position":8,"cik":"0001803809","reported_name":"BVF GP HOLDINGS LLC","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30216,"kind":"organization","name":"BVF INC/IL","position":9,"cik":"0001056807","reported_name":"BVF INC/IL","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}},{"id":30217,"kind":"person","name":"LAMPERT MARK N","position":10,"cik":"0001233840","reported_name":"LAMPERT MARK N","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":true,"other_text":"See Remarks and Footnotes"}}],"security":"Common Stock, $0.0001 par value","published_at":"2026-06-26T22:48:12.000Z","date":"2026-06-26","kind":"sale","planned":false,"acquired":false,"shares":837914,"price":106.5,"value":89237841.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 is filed jointly by Biotechnology Value Fund, L.P. (\"BVF\"), Biotechnology Value Fund II, L.P. (\"BVF2\"), Biotechnology Value Trading Fund OS LP (\"Trading Fund OS\"), BVF Partners OS Ltd. (\"Partners OS\"), BVF I GP LLC (\"BVF GP\"), BVF II GP LLC (\"BVF2 GP\"), BVF GP Holdings LLC (\"BVF GPH\"), BVF Partners L.P. (\"Partners\"), BVF Inc. and Mark N. Lampert (collectively, the \"Reporting Persons\"). Each of the Reporting Persons is a member of a Section 13(d) group. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF."}],"balance_after":1960881,"source":{"system":"sec-edgar","filing":"0000921895-26-001688","document":"form407422010_06262026.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1803809/000092189526001688/form407422010_06262026.xml","form_type":"4"}},{"id":726499,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T01:56:01.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":46,"price":129.61,"value":5962.06,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F13","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $129.3041 to $130.05 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":529718,"source":{"system":"sec-edgar","filing":"0001451612-26-000016","document":"form4-06262026_010658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":22,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000016/form4-06262026_010658.xml","form_type":"4"}},{"id":726498,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T01:56:01.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":305,"price":128.69,"value":39250.45,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F12","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $128.3008 to $129.2819 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":529764,"source":{"system":"sec-edgar","filing":"0001451612-26-000016","document":"form4-06262026_010658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":21,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000016/form4-06262026_010658.xml","form_type":"4"}},{"id":726497,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T01:56:01.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":3507,"price":127.37,"value":446686.59,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F11","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $127.30 to $128.2975 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":530069,"source":{"system":"sec-edgar","filing":"0001451612-26-000016","document":"form4-06262026_010658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":20,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000016/form4-06262026_010658.xml","form_type":"4"}},{"id":726496,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T01:56:01.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":223,"price":126.71,"value":28256.33,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $126.13 to $127.0511 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":533576,"source":{"system":"sec-edgar","filing":"0001451612-26-000016","document":"form4-06262026_010658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":19,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000016/form4-06262026_010658.xml","form_type":"4"}},{"id":726495,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T01:56:01.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":522,"price":125.82,"value":65678.04,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.1194 to $126.115 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":533799,"source":{"system":"sec-edgar","filing":"0001451612-26-000016","document":"form4-06262026_010658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":18,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000016/form4-06262026_010658.xml","form_type":"4"}},{"id":726494,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T01:56:01.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":1639,"price":124.61,"value":204235.79,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.09 to $125.0292 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":534321,"source":{"system":"sec-edgar","filing":"0001451612-26-000016","document":"form4-06262026_010658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":17,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000016/form4-06262026_010658.xml","form_type":"4"}},{"id":726493,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T01:56:01.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":1517,"price":123.62,"value":187531.54,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.09 to $124.08 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":535960,"source":{"system":"sec-edgar","filing":"0001451612-26-000016","document":"form4-06262026_010658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":16,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000016/form4-06262026_010658.xml","form_type":"4"}},{"id":726492,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T01:56:01.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":698,"price":122.67,"value":85623.66,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.0858 to $123.08 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":537477,"source":{"system":"sec-edgar","filing":"0001451612-26-000016","document":"form4-06262026_010658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":15,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000016/form4-06262026_010658.xml","form_type":"4"}},{"id":726491,"issuer":{"id":3545,"kind":"organization","name":"Kymera Therapeutics, Inc.","symbol":"KYMR"},"owners":[{"id":32920,"kind":"person","name":"Booth Bruce","position":1,"cik":"0001451612","reported_name":"Booth Bruce","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-06-26T01:56:01.000Z","date":"2026-06-25","kind":"sale","planned":true,"acquired":false,"shares":5689,"price":121.38,"value":690530.82,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by Atlas Venture Fund X, L.P. and Atlas Venture Opportunity Fund I, L.P. on December 11, 2025."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.08 to $122.0731 inclusive."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F14","text":"The shares are owned directly by Atlas Venture Opportunity Fund I, L.P. (\"AVOF\"). Atlas Venture Associates Opportunity I, L.P. (\"AVAO LP\") is the general partner of AVOF. Atlas Venture Associates Opportunity I, LLC (\"AVAO LLC\") is the general partner of AVAO LP. The Reporting Person is a member of AVAO LLC and disclaims Section 16 beneficial ownership of such securities held by AVOF, except to the extent of his pecuniary interest therein, if any."}],"balance_after":538175,"source":{"system":"sec-edgar","filing":"0001451612-26-000016","document":"form4-06262026_010658.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1815442/000145161226000016/form4-06262026_010658.xml","form_type":"4"}}],"next_cursor":"2026-06-26T01:56:01.000000Z,726491"}